Cost of drugs.
نویسندگان
چکیده
منابع مشابه
High cost of new drugs.
he investigation by The BMJ and Cambridge and Bath universities into the availability of breakthrough hepatitis C drugs raises important questions for NHS England about access to lifesaving drugs. But why are medicines so expensive in the first place? The pricing strategy of Gilead for sofosbuvir (Sovaldi) and ledipasvir-sofosbuvir (Harvoni) raises questions that go well beyond the UK. The BMJ'...
متن کاملControlling the cost of prescription drugs.
harmaceutical prices have risen draP l matically in the past 10 years and will I continue to escalate for the next two or three years, Michael Pollard told participants at Managing the Rising Cost of Drugs : A Mult idiscipl inary Approach to Improving Hospital Services, a November 1991 meeting held in Westborough, MA. Pollard, long-time pharmaceutical analyst and partner at the Washington, DC, ...
متن کاملCost-effectiveness and Pricing of Antibacterial Drugs
Growing resistance to antibacterial agents has increased the need for the development of new drugs to treat bacterial infections. Given increasing pressure on limited health budgets, it is important to study the cost-effectiveness of these drugs, as well as their safety and efficacy, to find out whether or not they provide value for money and should be reimbursed. In this article, we systematic...
متن کاملCost of anaesthetic drugs and clinical budgeting.
In 1980 Astley and Secker Walker calculated that the average total cost to the National Health Service of one anaesthetic was £29-98.' The cost of drugs for the year 1979-80 was £44 032 or 8 6% of the total hospital cost of anaesthesia of £506 459. This paper examines the drugs bill for the University College Hospital group of hospitals between April 1984 and March 1985 and compares it directly...
متن کاملCost-effectiveness of hypothetical new cancer drugs
Background: In the last decade, a number of new treatment modalities have been developed for patients with small cell lung cancer (SCLC). The clinical effects are encouraging, but little is known about the costs and cost-effectiveness of new drugs. Methods: A Markov chain model has been developed to project patient outcomes and costs for patients with advanced SCLC. All patients in the control ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1973
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.1.5850.416-a